Scholarlink

<p>Retinoblastoma (RB) is the most prevalent primary intraocular malignancy in children. N-acetyltransferase-like protein 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification is involved in regulating cancer progression. This study aimed to elucidate the role and underlying mechanisms of NAT10 in RB progression. The cell viability was detected by CCK-8 assay. The cell glycolysis was evaluated by glucose uptake, lactate production, extracellular acidification rate (ECAR), and oxygen consumption rate (OCR) assays. The underlying molecular mechanism was investigated by dot blot, western blot, quantitative real-time PCR, RNA immunoprecipitation (RIP), ac4C RIP, and dual-luciferase reporter assay. Results showed elevated NAT10 and ac4C levels in RB cells. Genetic modulation of NAT10 bidirectionally regulated glycolysis, with 2‑deoxy‑D‑glucose (2‑DG) attenuating NAT10-induced glycolytic activation. Mechanistically, NAT10 bound PFKFB3 and stabilized its mRNA via ac4C modification. PFKFB3 overexpression rescued glycolytic suppression caused by NAT10 knockdown. In vivo, NAT10 promoted tumor growth. Collectively, NAT10 contributes to RB progression by enhancing glycolysis through ac4C-mediated PFKFB3 mRNA stabilization, identifying the NAT10-ac4C-PFKFB3 axis as a potential therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NAT10 promotes the glycolysis of retinoblastoma through ac4C modification of PFKFB3 mRNA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月16日

查看全文
  • Zhen Li,
  • Weiwei Xie,
  • Layi Wang,
  • Guohai Wu

摘要

Retinoblastoma (RB) is the most prevalent primary intraocular malignancy in children. N-acetyltransferase-like protein 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification is involved in regulating cancer progression. This study aimed to elucidate the role and underlying mechanisms of NAT10 in RB progression. The cell viability was detected by CCK-8 assay. The cell glycolysis was evaluated by glucose uptake, lactate production, extracellular acidification rate (ECAR), and oxygen consumption rate (OCR) assays. The underlying molecular mechanism was investigated by dot blot, western blot, quantitative real-time PCR, RNA immunoprecipitation (RIP), ac4C RIP, and dual-luciferase reporter assay. Results showed elevated NAT10 and ac4C levels in RB cells. Genetic modulation of NAT10 bidirectionally regulated glycolysis, with 2‑deoxy‑D‑glucose (2‑DG) attenuating NAT10-induced glycolytic activation. Mechanistically, NAT10 bound PFKFB3 and stabilized its mRNA via ac4C modification. PFKFB3 overexpression rescued glycolytic suppression caused by NAT10 knockdown. In vivo, NAT10 promoted tumor growth. Collectively, NAT10 contributes to RB progression by enhancing glycolysis through ac4C-mediated PFKFB3 mRNA stabilization, identifying the NAT10-ac4C-PFKFB3 axis as a potential therapeutic target.